Clinical Evidence: Semaglutide and Sleep Apnea Outcomes A 2023 cardiovascular outcomes trial found that patients using semaglutide experienced a 39% relative risk reduction in obstructive sleep apnea severity compared to placebo, driven primarily by weight loss
In a study on HCC, we were pleasantly surprised to find that the HGF/c-MET pathway and FGF19/FGFR4 collaboratively enhance ETV4 expression in HCC cells via the ERK1/2 axis, where ETV4, an ETS transcription factor upregulated in all HCC stages, increases PD-L1 and CCL2 expression, resulting in MDSCs and TAMs infiltration, CD8 T cells suppression and HCC metastasis [79, 80]
Eating slowly and mindfully after your injectionwaiting 30 minutes before consuming a substantial mealallows your stomach to adapt gradually
Semaglutide has been in widespread use for longer than tirzepatide
According to an IQVIA article, by mid-2025, GLP-1s made up more than half of all diabetes prescriptions and 23% of all first-line starts (up from 3% in 2021), displacing metformin and other cheaper generics that historically start the diabetes treatment journey